

CARE ACROSS THE CANCER CONTINUUM



Screening



Prognosis &
Therapy Selection



Minimal Residual
Disease



Recurrence
Monitoring



Therapy
Guidance

Exact Sciences is changing the way we think about detecting and treating cancer. As a leader in cancer testing, we are committed to providing earlier answers and life-changing treatment guidance.

Exact Sciences' portfolio of products focuses on colorectal, breast, prostate, lung, and liver cancers, with research and development looking at 15 of the deadliest cancers, including multi-cancer screening.

From earlier cancer detection to treatment guidance and monitoring, the company aims to offer a comprehensive suite of tests to enable the delivery of personalized care across the cancer continuum.

CANCER IS DETECTED TOO LATE

Cancer is a thief. It robs us of our family members, of our comfort, of once-in-a-lifetime opportunities. But most of all, cancer is a stealer of time. But what if we could steal time back? What if we could transform the suffering caused by cancer into the joy of living a full and thriving life? **We believe we can help make this world a reality.**

1 in 5

diagnosed with cancer
in their lifetime¹

1 in 6

deaths worldwide
attributed to cancer²

10M

total annual
cancer deaths³

CHANGING LIVES, TOGETHER

Exact Sciences is uniquely positioned to impact patients across the cancer continuum through **our global team, our capabilities and infrastructure, and our dedication to taking on the impossible.** We are continuously innovating, combining scientific rigor with an open-minded approach to deliver the next big thing.

Over 4M

people tested in 2020⁴

Over 5,500

global employees⁴

5

clinical laboratories⁴
(WI, CA, AZ)

Exact Sciences understands the need to invest in our backyard, as well as the global community, **to improve health, defeat cancer, and leave a better planet for the next generation.** We support United Way's campaigns to improve lives around the world through education, health, and financial stability. We also collaborate with the Urban League of Greater Madison, where we are headquartered, to offer free job skills training to community members.

PRODUCT PORTFOLIO

Cologuard®

Cologuard is a stool DNA-based test for colorectal cancer screening for average-risk patients 45 and older⁵. It is effective, non-invasive, and FDA approved. Cologuard is a convenient option that patients can use in the privacy of their own homes, with no special prep, time off or changes in diet or medication necessary. Cologuard finds 92% of colon cancers, even in early stages⁵. Cologuard is not for high-risk individuals. In 2019, the FDA approved Cologuard for use in eligible average-risk adults, starting at age 45, expanding on its previous indication for ages 50 and older.

Oncoguard™ Liver

The Oncoguard™ Liver solution was designed with the hope of bringing better outcomes to more people at risk of Hepatocellular Carcinoma (HCC), the most common form of liver cancer. The sophisticated, yet simple, blood test is for adults with liver cirrhosis and/or chronic hepatitis B (HBV) who are at risk for HCC. Designed for high performance to enable early-stage detection⁶, the test is complemented by a Patient Engagement Program to help empower patients to proactively protect their health and follow through with routine testing. Together, the Oncoguard™ Liver solution offers a streamlined approach to liver cancer detection.

Oncotype DX®

Every cancer is unique and affects each diagnosed person differently based on the individual biology of their disease. To address this diversity and make cancer care smarter at every stage, our Oncotype DX diagnostic tests and services portfolio delivers clinically relevant genomic intelligence specific to the individual biology of a patient's tumor. This additional genomic insight helps physicians optimize treatment decisions for breast, colon, and prostate cancers.

Oncotype MAP™ Pan-Cancer Tissue

The Oncotype MAP Pan-Cancer Tissue test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. The test identifies actionable genomic alterations within 3-5 business days^{4†} and with small tissue sample sizes⁴, helping guide timely discussions and decisions, while helping physicians to understand a patient's tumor profile to recommend targeted therapies or clinical trials.

GEM ExTra®

The GEM ExTra test detects damage in tumor genes and provides an extensive biological picture of certain refractory, rare, or aggressive cancers. With an extensive panel of approximately 20,000 genes and 169 introns, the GEM ExTra test is a comprehensive panel including both genomic (DNA) and transcriptomic (RNA) panels. It provides physicians, academic medical centers, and biopharma researchers with vital interpreted information to understand changes to a patient's tumor genomic profile to recommend therapeutic treatment plans.⁷

OUR PIPELINE

Building on the success of the Cologuard and Oncotype® tests, the company is investing in its product pipeline across the cancer continuum. We are collaborating with Mayo Clinic, Johns Hopkins University, The Translational Genomics Research Institute (an affiliate of City of Hope), and others to develop new cancer tests. Using proprietary DNA chemistry and a flexible automated laboratory platform, the goal is to develop tests that detect cancers in their earliest, most treatable stages. A blood-based test in development has the potential to make routine screening for multiple types of cancer a reality. We are also developing solutions for minimal residual disease (MRD) testing.

† Turnaround time is based on qualified sample receipt.

Sources

1. World Health Organization International Agency for Research on Cancer. GLOBOCAN 2020: new global cancer data. Published February 15, 2021. Accessed June 17, 2021. <https://www.uicc.org/news/globocan-2020-new-global-cancer-data>

2. World Health Organization. Health topics: cancer. Accessed June 17, 2021. https://www.who.int/health-topics/cancer#tab=tab_1

3. World Health Organization International Agency for Research on Cancer. GLOBOCAN 2020: all cancers fact sheet. Accessed June 17, 2021. <https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf>

4. Internal Data on File. Exact Sciences Corporation, Madison, WI.

5. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med*. 2014;370(14):1287-1297. doi:10.1056/NEJMoa1311194

6. Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ. Validation of a novel multi-target blood test shows high sensitivity to detect early-stage hepatocellular carcinoma. *Clinical Gastroenterology and Hepatology* (2021). doi: <https://doi.org/10.1016/j.cgh.2021.08.010>

7. Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. *Sci Transl Med*. 2015;7(283):283ra53. doi:10.1126/scitranslmed.aaa7161

For more information on Exact Sciences, please visit the company's website www.exactsciences.com and follow Exact Sciences on Twitter, Facebook or LinkedIn.



EXACT SCIENCES

Cologuard, Oncoguard, GEM ExTra, and Exact Sciences are registered trademarks of Exact Sciences Corporation.

Oncotype, Oncotype DX, and Oncotype MAP Pan-Cancer Tissue are trademarks of Genomic Health, Inc. (a wholly owned subsidiary of Exact Sciences Corporation). All other trademarks are the properties of their respective owners.

© 2021 Exact Sciences Corporation. All rights reserved.